Patents by Inventor Elena S. Koltun

Elena S. Koltun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAS INHIBITORS
    Publication number: 20250145643
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: July 3, 2024
    Publication date: May 8, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • RAS INHIBITORS
    Publication number: 20250129097
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: December 9, 2024
    Publication date: April 24, 2025
    Inventors: James CREGG, Adrian L. Gill, Elena S. Koltun, John E. Knox
  • Ras inhibitors
    Patent number: 12280113
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: April 22, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Elena S. Koltun, James Cregg, Yang Liu, Adrian L. Gill
  • MEK INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20250100966
    Abstract: Disclosed am compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and am useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
    Type: Application
    Filed: May 23, 2024
    Publication date: March 27, 2025
    Inventors: Naing Aay, Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Anagha Abhijit Joshi, Abigail R Kennedy, Angie Inyoung Kim, Elena S. Koltun, Jean-Claire Limun Manalo, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang
  • Bicyclic heteroaryl compounds and uses thereof
    Patent number: 12258366
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: March 25, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • Ras inhibitors
    Patent number: 12252497
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: March 18, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Jennifer Pitzen, Christopher Semko
  • RAS INHIBITORS
    Publication number: 20250074923
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 14, 2024
    Publication date: March 6, 2025
    Inventors: John E. KNOX, Elena S. KOLTUN, Yang LIU, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, Andreas BUCKL, Christopher SEMKO
  • RAS INHIBITORS
    Publication number: 20250051306
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 29, 2024
    Publication date: February 13, 2025
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, Christopher Semko, Micah James Gliedt, John E. Knox, William D. Thomas
  • Ras inhibitors
    Patent number: 12202845
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: January 21, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: John E. Knox, Elena S. Koltun, Yang Liu, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, Andreas Buckl, Christopher Semko
  • RAS INHIBITORS
    Publication number: 20240400523
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 1, 2024
    Publication date: December 5, 2024
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
  • Monocyclic compounds useful as GPR120 modulators
    Patent number: 12116362
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: October 15, 2024
    Assignee: Valo Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20240262847
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 3, 2023
    Publication date: August 8, 2024
    Inventors: G. Leslie BURNETT, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN
  • BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240199616
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: July 10, 2023
    Publication date: June 20, 2024
    Inventors: Brian R. BLANK, Jennifer PITZEN, Gang WANG, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Elena S. KOLTUN, Naing AAY, Andreas BUCKL, Kevin MELLEM, Christopher SEMKO, Ash JOGALEKAR, Gert KISS, Adrian GILL
  • COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF
    Publication number: 20240139185
    Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 16, 2023
    Publication date: May 2, 2024
    Inventors: Meizhong JIN, Nicholas Perl, Anna Kohlmann, Ning Yin, Jason T. Lowe, Jae Young Ahn, Mark Joseph Mulvihill, Elena S. Koltun, Adrian L. Gill
  • 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240116878
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: March 21, 2023
    Publication date: April 11, 2024
    Inventors: Elena S. KOLTUN, Kevin MELLEM, Adrian GILL, Gert KISS, Christopher SEMKO, Naing AAY, Andreas BUCKL, Ashutosh JOGALEKAR, Walter WON
  • Ras inhibitors
    Patent number: 11952352
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: April 9, 2024
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, James Cregg, Elena S. Koltun, Yang Liu
  • POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240101577
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 17, 2023
    Publication date: March 28, 2024
    Inventors: Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
  • PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240092795
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: April 25, 2023
    Publication date: March 21, 2024
    Inventors: Adrian GILL, Naing AAY, Kevin MELLEM, Andreas BUCKL, Elena S. KOLTUN, Christopher SEMKO, Gert KISS
  • Bicyclic compounds useful as GPR120 modulators
    Patent number: 11919891
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Valo Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240067636
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: April 5, 2023
    Publication date: February 29, 2024
    Inventors: Jie Jack LI, Elena S. KOLTUN, Adrian Liam GILL, Andreas BUCKL, Walter WON, Naing AAY, Kevin MELLEM, Christos TZITZILONIS, Ashutosh JOGALEKAR, James Joseph CREGG